Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study.

J Thorens, F Froehlich, W Schwizer, E Saraga, J Bille, K Gyr, P Duroux, M Nicolet, B Pignatelli, A L Blum, J J Gonvers, M Fried

Department of Gastroenterology, University Hospital, Lausanne, Switzerland.

BACKGROUND: Gastric and duodenal bacterial overgrowth frequently occurs in conditions where diminished acid secretion is present. Omeprazole inhibits acid secretion more effectively than cimetidine and might therefore more frequently cause bacterial overgrowth. AIM: This controlled prospective study compared the incidence of gastric and duodenal bacterial overgrowth in patients treated with omeprazole or cimetidine. METHODS: 47 outpatients with peptic disease were randomly assigned to a four week treatment regimen with omeprazole 20 mg or cimetidine 800 mg daily. Gastric and duodenal juice were obtained during upper gastrointestinal endoscopy and plated for anaerobic and aerobic organisms. RESULTS: Bacterial overgrowth (> or = 10(5) cfu/ml) was present in 53% of the patients receiving omeprazole and in 17% receiving cimetidine (p < 0.05). The mean (SEM) number of gastric and duodenal bacterial counts was 6.0 (0.2) and 5.0 (0.2) respectively in the omeprazole group and 4.0 (0.2) and 4.0 (0.1) in the cimetidine group (p < 0.001 and < 0.01; respectively). Faecal type bacteria were found in 30% of the patients with bacterial overgrowth. Basal gastric pH was higher in patients treated with omeprazole compared with cimetidine (4.2 (0.5) versus 2.0 (0.2); p < 0.001) and in patients with bacterial overgrowth compared with those without bacterial overgrowth (5.1 (0.6) versus 2.0 (0.1); p < 0.0001). The nitrate, nitrite, and nitrosamine values in gastric juice did not increase after treatment with either cimetidine or omeprazole. Serum concentrations of vitamin B12, beta carotene, and albumin were similar before and after treatment with both drugs. CONCLUSIONS: These results show that the incidence of gastric and duodenal bacterial overgrowth is considerably higher in patients treated with omeprazole compared with cimetidine. This can be explained by more pronounced inhibition of gastric acid secretion. No patient developed signs of malabsorption or an increase of N-nitroso compounds. The clinical significance of these findings needs to be assessed in studies with long-term treatment with omeprazole, in particular in patients belonging to high risk groups such as HIV infected and intensive care units patients.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Wise, M. P., Saayman, A. G., Frost, P. J. (2009). Acid-Suppressive Medication and Hospital-Acquired Pneumonia. JAMA 302: 1416-1416 [Full Text]  
• Miano, T. A., Reichert, M. G., Houle, T. T., MacGregor, D. A., Kincaid, E. H., Bowton, D. L. (2009). Nosocomial Pneumonia Risk and Stress Ulcer Prophylaxis: A Comparison of Pantoprazole vs Ranitidine in Cardiothoracic Surgery Patients. Chest 136: 440-447 [Abstract] [Full Text]  
• Hsu, C.-S., Kao, J.-H., Lenglinger, J., Riegler, M., Wise, M. P., Saayman, A. G., Frost, P. J., Wise, R. A., the Writing Committee of the American Lung Associa, (2009). Esomeprazole for asthma.. NEJM 361: 206-207 [Full Text]  
• Halsey, J. (2008). Current and future treatment modalities for Clostridium difficile-associated disease. Am J Health Syst Pharm 65: 705-715 [Abstract] [Full Text]  
• Cat, T. B, Charash, W., Hebert, J., Marden, B. T, Corbett, S. M., Ahern, J., Rebuck, J. A (2008). Potential Influence of Antisecretory Therapy on the Development of Candida-Associated Intraabdominal Infection. The Annals of Pharmacotherapy 42: 185-191 [Abstract] [Full Text]  
• Jump, R. L. P., Pultz, M. J., Donskey, C. J. (2007). Vegetative Clostridium difficile Survives in Room Air on Moist Surfaces and in Gastric Contents with Reduced Acidity: a Potential Mechanism To Explain the Association between Proton Pump Inhibitors and C. difficile-Associated Diarrhea?. Antimicrob. Agents Chemother. 51: 2883-2887 [Abstract] [Full Text]  
• Stiefel, U., Rao, A., Pultz, M. J., Jump, R. L. P., Aron, D. C., Donskey, C. J. (2006). Suppression of Gastric Acid Production by Proton Pump Inhibitor Treatment Facilitates Colonization of the Large Intestine by Vancomycin-Resistant Enterococcus spp. and Klebsiella pneumoniae in Clindamycin-Treated Mice. Antimicrob. Agents Chemother. 50: 3905-3907 [Abstract] [Full Text]  
• Canani, R. B., Cirillo, P., Roggero, P., Romano, C., Malamisura, B., Terrin, G., Passariello, A., Manguso, F., Morelli, L., Guarino, A., for the Working Group on Intestinal Infections of, (2006). Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children. Pediatrics 117: e817-e820 [Abstract] [Full Text]  
• Dial, S., Delaney, J. A. C., Barkun, A. N., Suissa, S. (2005). Use of Gastric Acid-Suppressive Agents and the Risk of Community-Acquired Clostridium difficile-Associated Disease. JAMA 294: 2989-2995 [Abstract] [Full Text]  
• Schreiber, S., Bucker, R., Groll, C., Azevedo-Vethacke, M., Garten, D., Scheid, P., Friedrich, S., Gatermann, S., Josenhans, C., Suerbaum, S. (2005). Rapid Loss of Motility of Helicobacter pylori in the Gastric Lumen In Vivo. Infect. Immun. 73: 1584-1589 [Abstract] [Full Text]  
• Laheij, R. J. F., Sturkenboom, M. C. J. M., Hassing, R.-J., Dieleman, J., Stricker, B. H. C., Jansen, J. B. M. J. (2004). Risk of Community-Acquired Pneumonia and Use of Gastric Acid-Suppressive Drugs. JAMA 292: 1955-1960 [Abstract] [Full Text]  
• Dial, S., Alrasadi, K., Manoukian, C., Huang, A., Menzies, D. (2004). Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 171: 33-38 [Abstract] [Full Text]  
• Salvatore, S., Vandenplas, Y. (2002). Gastroesophageal Reflux and Cow Milk Allergy: Is There a Link?. Pediatrics 110: 972-984 [Abstract] [Full Text]  
• Madi-Szabo, L. (2002). Exclusive Interview With Helicobacter pylori. JAMA 287: 1619-1620 [Full Text]  
• SHAH, S., LEWIS, A., LEOPOLD, D., DUNSTAN, F., WOODHOUSE, K. (2000). Gastric acid suppression does not promote clostridial diarrhoea in the elderly. QJM 93: 175-181 [Abstract] [Full Text]  
• Elliott, S. N., Wallace, J. L., McKnight, W., Gall, D. G., Hardin, J. A., Olson, M., Buret, A. (2000). Bacterial colonization and healing of gastric ulcers: the effects of epidermal growth factor. Am. J. Physiol. Gastrointest. Liver Physiol. 278: G105-G112 [Abstract] [Full Text]  
• Nehra, D, Howell, P, Williams, C P, Pye, J K, Beynon, J (1999). Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut 44: 598-602 [Abstract] [Full Text]  
• Wilcox, C M, Waites, K B, Smith, P D (1999). No relationship between gastric pH, small bowel bacterial colonisation, and diarrhoea in HIV-1 infected patients. Gut 44: 101-105 [Abstract] [Full Text]  
• MURPHY, G M (1998). Depressing acid, deconjugating bile. Gut 42: 154-155 [Full Text]  
• Shindo, K, Machida, M, Fukumura, M, Koide, K, Yamazaki, R (1998). Omeprazole induces altered bile acid metabolism. Gut 42: 266-271 [Abstract] [Full Text]